197 related articles for article (PubMed ID: 20953290)
1. Pharmacological Preconditioning with GYKI 52466: A Prophylactic Approach to Neuroprotection.
Goulton CS; Patten AR; Kerr JR; Kerr DS
Front Neurosci; 2010; 4():. PubMed ID: 20953290
[TBL] [Abstract][Full Text] [Related]
2. Low-dose GYKI-52466: prophylactic preconditioning confers long-term neuroprotection and functional recovery following hypoxic-ischaemic brain injury.
Nayak PK; Kerr DS
Neuroscience; 2013 Mar; 232():128-38. PubMed ID: 23246617
[TBL] [Abstract][Full Text] [Related]
3. Kainate receptor agonists and antagonists mediate tolerance to kainic acid and reduce high-affinity GTPase activity in young, but not aged, rat hippocampus.
Hesp BR; Wrightson T; Mullaney I; Kerr DS
J Neurochem; 2004 Jul; 90(1):70-9. PubMed ID: 15198668
[TBL] [Abstract][Full Text] [Related]
4. Functional preservation of hippocampal CA1 by low-dose GYKI-52466 preconditioning in a rat model of hypoxic-ischemic brain injury.
Nayak PK; Kerr DS
Brain Res; 2015 Jul; 1613():100-9. PubMed ID: 25869178
[TBL] [Abstract][Full Text] [Related]
5. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil.
Löscher W; Hönack D
Br J Pharmacol; 1994 Dec; 113(4):1349-57. PubMed ID: 7889291
[TBL] [Abstract][Full Text] [Related]
6. In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466.
Lees GJ; Leong W
Brain Res; 2001 Jan; 890(1):66-77. PubMed ID: 11164769
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal damage after intra-amygdala kainic acid-induced status epilepticus and seizure preconditioning-mediated neuroprotection in SJL mice.
Tanaka K; Jimenez-Mateos EM; Matsushima S; Taki W; Henshall DC
Epilepsy Res; 2010 Feb; 88(2-3):151-61. PubMed ID: 19931419
[TBL] [Abstract][Full Text] [Related]
8. Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.
Borowicz KK; Duda AM; Kleinrok Z; Czuczwar SJ
Pol J Pharmacol; 2001; 53(2):101-8. PubMed ID: 11787948
[TBL] [Abstract][Full Text] [Related]
9. NMDA preconditioning and neuroprotection in vivo: delayed onset of kainic acid-induced neurodegeneration and c-Fos attenuation in CA3a neurons.
Mohammadi S; Pavlik A; Krajci D; Al-Sarraf H
Brain Res; 2009 Feb; 1256():162-72. PubMed ID: 19118538
[TBL] [Abstract][Full Text] [Related]
10. Spectral analysis of electrocorticographic activity during pharmacological preconditioning and seizure induction by intrahippocampal domoic acid.
Sawant PM; Mountfort DO; Kerr DS
Hippocampus; 2010 Aug; 20(8):994-1002. PubMed ID: 19714566
[TBL] [Abstract][Full Text] [Related]
11. Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling.
Weiczner R; Krisztin-Péva B; Mihály A
Epilepsy Res; 2008 Jan; 78(1):22-32. PubMed ID: 18036781
[TBL] [Abstract][Full Text] [Related]
12. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.
Liljequist S; Cebers G; Kalda A
Biochem Pharmacol; 1995 Nov; 50(11):1761-74. PubMed ID: 8615854
[TBL] [Abstract][Full Text] [Related]
13. GYKI 52466 protects against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures.
May PC; Robison PM
Neurosci Lett; 1993 Apr; 152(1-2):169-72. PubMed ID: 8100052
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective neuroprotection by novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures.
May PC; Robison PM; Fuson KS
Neurosci Lett; 1999 Mar; 262(3):219-21. PubMed ID: 10218895
[TBL] [Abstract][Full Text] [Related]
15. Determination of 1-(4'-aminophenyl)-4-methyl-7,8-methylene-dioxy-2,3-benzodiazepine by high-performance liquid chromatography-diode array detection in plasma and brain in healthy and hypoxic-ischaemic rats.
Nayak PK; Zhang H; Kerr DS
Neuroscience; 2013 Mar; 232():139-50. PubMed ID: 23232259
[TBL] [Abstract][Full Text] [Related]
16. Evidence that GYKI 52466, a novel non-NMDA antagonist enhances the decay of kainate-induced current in cultured chicken cortical neurons.
Osipenko O; Mike A; Gyevai A; Vizi ES
Brain Res Dev Brain Res; 1994 Feb; 77(2):257-63. PubMed ID: 7513623
[TBL] [Abstract][Full Text] [Related]
17. Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist.
Ruel J; Guitton MJ; Puell JL
CNS Drug Rev; 2002; 8(3):235-54. PubMed ID: 12353057
[TBL] [Abstract][Full Text] [Related]
18. Modulation of kainate-induced responses by pentobarbitone and GYKI-53784 in rat abducens motoneurons in vivo.
Ruiz A; Durand J
Brain Res; 1999 Feb; 818(2):421-30. PubMed ID: 10082828
[TBL] [Abstract][Full Text] [Related]
19. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels.
Plamondon H; Blondeau N; Heurteaux C; Lazdunski M
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1296-308. PubMed ID: 10598933
[TBL] [Abstract][Full Text] [Related]
20. Interactions of GYKI 52466 and NBQX with cyclothiazide at AMPA receptors: experiments with outside-out patches and EPSCs in hippocampal neurones.
Rammes G; Swandulla D; Spielmanns P; Parsons CG
Neuropharmacology; 1998; 37(10-11):1299-320. PubMed ID: 9849667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
